AI assistant
CorMedix Inc. — Director's Dealing 2013
Mar 22, 2013
32333_dirs_2013-03-22_13b36fa2-b74e-4514-bd05-c51fa04ed9ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-03-20
Reporting Person: MILBY RANDY (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-03-20 | Stock Option (right to buy) | $0.9 | A | 500000 | Acquired | 2023-03-20 | Common Stock, $0.001 par value per share (500000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.68 | 2022-12-05 | Common Stock, $0.001 par value per share (100000) | 100000 | Indirect |
| Senior Convertible Note (convertible into Common Stock) | $0.35 | 2013-09-20 | Common Stock, $0.001 par value per share (142857) | 142857 | Indirect |
| Warrant (right to purchase Common Stock) | $0.4 | 2017-09-20 | Common Stock, $0.001 par value per share (125000) | 125000 | Indirect |
| Stock Option (right to buy) | $0.29 | 2022-05-14 | Common Stock, $0.001 par value per share (50000) | 50000 | Indirect |
Footnotes
F1: These options vest based on performance milestones running through December 31, 2014.
F2: These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.
F3: The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).
F4: On September 20, 2012, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement $50,000 of (i) 9% Senior Convertible Notes, convertible into shaers of the Company's Common Stock, $0.001 par value per share, at a conversion price of $0.35 per share; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
F5: These options vest 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate.